References
- 1. World Health Organization, Epilepsy Fact Sheet, WHO, June 2019, Geneve; https://www.who.int/news-room/fact-sheets/detail/epilepsy; last access date October 28, 2020.
- 2. E. Beghi, The epidemiology of epilepsy, Neuroepidemiology54 (2020) 185–191; https://doi.org/10.1159/00050383110.1159/000503831
- 3. N. Kuroda, Epilepsy and COVID-19: Associations and important considerations, Epilepsy Behav.108 (2020) Article ID 107122 (3 pages); https://doi.org/10.1016/j.yebeh.2020.10712210.1016/j.yebeh.2020.107122
- 4. H. P. Rang, M. M. Dall, J. M. Ritter and R. J. Flower, Antiepileptic Drugs, in Rang and Dale’s Pharmacology, Elsevier, Amsterdam 2007, pp. 540–551.10.1016/B978-0-443-06911-6.50045-1
- 5. R. S. Fisher, W. van Emde Boas, W. Blume, C. Elger, P. Genton, P. Lee and J. Jr. Engel, Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE), Epilepsia46 (2005) 470–472; https://doi.org/10.1111/j.0013-9580.2005.66104.x10.1111/j.0013-9580.2005.66104.x
- 6. S. Engelborghs, R. D’Hooge and P. P. De Deyn, Pathophysiology of epilepsy, Acta Neurol. Belg.100 (2000) 201–213.
- 7. P. Genton, P. Gelisse, P. Thomas and C. Dravet, Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology55 (2000) 1106–1109; https://doi.org/10.1212/wnl.55.8.110610.1212/WNL.55.8.1106
- 8. S. C. Schachter, Currently available antiepileptic drugs, Neurotherapeutics4 (2007) 4–11; https://doi.org/10.1016/j.nurt.2006.11.00510.1016/j.nurt.2006.11.005
- 9. D. G. Vossler, M. Weingarten and B. E. Gidal, Summary of antiepileptic drugs available in the United States of America, Epilepsy Curr. 18 (2018) 1–26; https://doi.org/10.5698/1535-7597.18.4s1.110.5698/1535-7597.18.4s1.1
- 10. E. Perucca and T. Tomson, The pharmacological treatment of epilepsy in adults, Lancet Neurol.10 (2011) 446–456; https://doi.org/10.1016/S1474-4422(11)70047-310.1016/S1474-4422(11)70047-3
- 11. D. Schmidt and W. Loscher, Drug resistance in epilepsy, putative neurobiologic and clinical mechanisms, Epilepsia46 (2005) 858–877; https://doi.org/10.1111/j.1528-1167.2005.54904.x10.1111/j.1528-1167.2005.54904.x15946327
- 12. S. Beyenburg, J. Bauer and M. Reuber, New drugs for the treatment of epilepsy: a practical approach, Postgrad. Med. J.80 (2004) 581–587; https://doi.org/10.1136/pgmj.2004.01997610.1136/pgmj.2004.019976174310715466993
- 13. S. K. Bhattacharya, G. P. Rauniar and B. P. Das, Recent advances in the management of epilepsy: a review, Kathmandu Univ. Med. J. (KUMJ)3 (2005) 431–437.
- 14. R. S. Fisher and J. Ho, Potential new methods for antiepileptic drug delivery, CNS Drugs16 (2002) 579–593; https://doi.org/10.2165/00023210-200216090-0000110.2165/00023210-200216090-00001
- 15. R. S. Fisher and D. K. Chen, New routes for delivery of anti-epileptic medications, Acta Neurol. Taiwan15 (2006) 225–231.
- 16. J. H. Sampson, M. L. Brady, N. A. Petry, D. Croteau, A. H. Friedman, H. S. Friedman, T. Wong, D. D. D. Bigner, I. Pastan, R. K. K. Puri and C. Pedain, Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning, Neurosurgery60 (2007) ONS-89-ONS-98; https://doi.org/10.1227/01.NEU.0000249256.09289.5F10.1227/01.NEU.0000249256.09289.5F
- 17. M. A. Rogawski, Convection-enhanced delivery in the treatment of epilepsy, Neurotherapeutics6 (2009) 344–351; https://doi.org/10.1016/j.nurt.2009.01.01710.1016/j.nurt.2009.01.017
- 18. A. Van Dycke, R. Raedt, K. Vonck and P. Boon, Local delivery strategies in epilepsy: a focus on adenosine, Seizure20 (2011) 376–382; https://doi.org/10.1016/j.seizure.2011.03.00310.1016/j.seizure.2011.03.003
- 19. N. Mori, A. Kurokouchi, K. Osonoe, H. Saitoh, K. Ariga, K. Suzuki and Y. Iwata, Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats, Brain Res.703 (1995) 184–190; https://doi.org/10.1016/0006-8993(95)01095-510.1016/0006-8993(95)01095-5
- 20. M. F. Bennewitz and W. M. Saltzman, Nanotechnology for delivery of drugs to the brain for epilepsy, Neurotherapeutics6 (2009) 323–336; https://doi.org/10.1016/j.nurt.2009.01.01810.1016/j.nurt.2009.01.018
- 21. Y. Malam, E. J. Lim and A. M. Seifalian, Current trends in the application of nanoparticles in drug delivery, Curr. Med. Chem. 18 (2011) 1067–1078; https://doi.org/10.2174/09298671179494086010.2174/092986711794940860
- 22. M.-H. Hsiao, M. Larsson, A. Larsson, H. Evenbratt, Y.-Y. Chen, Y.-Y. Chen and D.-M. Liu, Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide, J. Control. Release161 (2012) 942–948; https://doi.org/10.1016/j.jconrel.2012.05.03810.1016/j.jconrel.2012.05.038
- 23. M. D. Farwell, D. J. Chong, Y. Iida, S. A. Bae, B. Easwaramoorthy and M. Ichise, Imaging P-glyco-protein function in rats using [(11) C]-N-desmethyl-loperamide, Ann. Nucl. Med. 27 (2013) 618–24; https://doi.org/10.1007/s12149-013-0725-510.1007/s12149-013-0725-5
- 24. R. J. Tamargo, L. A. Rossell, E. H. Kossoff, B. M. Tyler, M. G. Ewend and J. J. Aryanpur, The intra-cerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats, Epilepsy Res.48 (2002) 145–155; https://doi.org/10.1016/s0920-1211(01)00330-810.1016/S0920-1211(01)00330-8
- 25. H. G. Eder, D. B. Jones and R. S. Fisher, Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats, Epilepsia38 (1997) 516–521; https://doi.org/10.1111/j.1528-1157.1997.tb01134.x10.1111/j.1528-1157.1997.tb01134.x9184595
- 26. M. H. Semreen, A. N. El-Shorbagi, T. H. Al-Tel and I. M. Alsalahat, Targeting γ-aminobutyric acid (GABA) carriers to the brain: potential relevance as antiepileptic pro-drugs, Med. Chem.6 (2010) 144–149; https://doi.org/10.2174/157340641100603014410.2174/157340641100603014420632978
- 27. A. H. Ropper, Hyperosmolar therapy for raised intracranial pressure, N. Engl. J. Med.367 (2012) 746–752; https://doi.org/10.1056/NEJMct120632110.1056/NEJMct120632122913684
- 28. A. J. Halliday, S. E. Moulton, G. G. Wallace and M. J. Cook, Novel methods of antiepileptic drug delivery – polymer-based implants, Adv. Drug Deliv. Rev.64 (2012) 953–964; https://doi.org/10.1016/j.addr.2012.04.00410.1016/j.addr.2012.04.00422564384
- 29. A. Thakker and P. Shanbag, A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures, J. Neurol. 260 (2013) 470–474; https://doi.org/10.1007/s00415-012-6659-310.1007/s00415-012-6659-322983456
- 30. J. M. Pellock, Safety of diastat, a rectal gel formulation of diazepam for acute seizure treatment, Drug Safety27 (2004) 383–392; https://doi.org/10.2165/00002018-200427060-0000310.2165/00002018-200427060-0000315144232
- 31. G. J. de Haan, P. van der Geest, G. Doelman, E. Bertram and P. A. Edelbroek, A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations, Epilepsia51 (2010) 478–482; https://doi.org/10.1111/j.1528-1167.2009.02333.x10.1111/j.1528-1167.2009.02333.x19817813
- 32. A. Okumura, T. Tanabe, T. Kato, F. Hayakawa and K. Watanabe, A pilot study on lidocaine tape therapy for convulsions with mild gastroenteritis, Brain Dev.26 (2004) 525–529; https://doi.org/10.1016/j.braindev.2004.02.00910.1016/j.braindev.2004.02.00915533654
- 33. K. Mori, H. Ito, Y. Toda, T. Hashimoto, M. Miyazaki, T. Saijo and Y. Kuroda, Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion, Epilepsia45 (2004) 1287–1290; https://doi.org/10.1111/j.0013-9580.2004.17304.x10.1111/j.0013-9580.2004.17304.x15461684
- 34. C. Harada, T. Hirai, Y. Fujii, S. Harusawa, T. Kurihara and C. Kamei, Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia, Methods Find. Exp. Clin. Pharmacol.26 (2004) 263–270.
- 35. J. A. Barcia and J. M. Gallego, Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model, Neurotherapeutics6 (2009) 337–343; https://doi.org/10.1016/j.nurt.2009.01.01510.1016/j.nurt.2009.01.015508421219332328
- 36. M. Yildirim and C. Marangoz, Anticonvulsant effects of focal and intracerebroventricular adenosine on penicillin-induced epileptiform activity in rats, Brain Res.1127 (2006) 193–200; https://doi.org/10.1016/j.brainres.2006.10.02410.1016/j.brainres.2006.10.024
- 37. A. Misra, S. Ganesh, A. Shahiwala and S. P. Shah, Drug delivery to the central nervous system: a review, J. Pharm. Pharm. Sci.6 (2003) 252–273.
- 38. J. M. Gonzàlez-Darder, E. Gómez-Cárdenas, M. Guerrero, D. Segura-Pastor and J. L. Gil-Salú, Intrathecal antiepileptic drugs in experimental epilepsy, Stereotact. Funct. Neurosurg.57 (1991) 147–155; https://doi.org/10.1159/00009956610.1159/000099566
- 39. V. Buonaguro, B. Scelsa, D. Curci, S. Monforte, T. Iuorno and F. Motta, Epilepsy and intrathecal baclofen therapy in children with cerebral palsy, Pediatr. Neurol.33 (2005) 110–113; https://doi.org/10.1016/j.pediatrneurol.2005.03.00210.1016/j.pediatrneurol.2005.03.002
- 40. V. Riban, H. L. Fitzsimons and M. J. During, Gene therapy in epilepsy, Epilepsia50 (2009) 24–32; https://doi.org/10.1111/j.1528-1167.2008.01743.x10.1111/j.1528-1167.2008.01743.x
- 41. M. C. Walker, S. Schorge, D. M. Kullmann, R. C. Wykes, J. H. Heeroma and L. Mantoan, Gene therapy in status epilepticus, Epilepsia54 (2013) 43–45; https://doi.org/10.1111/epi.1227510.1111/epi.12275
- 42. W. Löscher, M. Gernert and U. Heinemann, Cell and gene therapies in epilepsy – promising avenues or blind alleys? Trends Neurosci.31 (2008) 62–73; https://doi.org/10.1016/j.tins.2007.11.01210.1016/j.tins.2007.11.012
- 43. A. Mountain, Gene therapy: The first decade, Trends Biotechnol.18 (2000) 119–128; https://doi.org/10.1016/s0167-7799(99)01416-x10.1016/S0167-7799(99)01416-X
- 44. M. Simonato, Gene therapy for epilepsy, Epilepsy Behav.38 (2014) 125–130; https://doi.org/10.1016/j.yebeh.2013.09.01310.1016/j.yebeh.2013.09.01324100249
- 45. G. J. Sills, Novel therapeutic strategies for epilepsy-releasing the gene Genie, Epilepsy Curr.9 (2009) 26–27; https://doi.org/10.1111/j.1535-7511.2008.01280.x10.1111/j.1535-7511.2008.01280.x266811319396346
- 46. M. Baulac and A. Pitkänen, Research priorities in epilepsy for the next decade – a representative view of the European scientific community, Epilepsia50 (2009) 571–578; https://doi.org/10.1111/j.1528-1167.2008.01811.x10.1111/j.1528-1167.2008.01811.x
- 47. D. K. Nguyen and S. S. Spencer, Recent advances in the treatment of epilepsy, Arch Neurol.60 (2003) 929–935; https://doi.org/10.1001/archneur.60.7.92910.1001/archneur.60.7.92912873848
- 48. Epilepsy Foundation, Seizure Medication List, Landover (MD), September 2010; https://www.epilepsy.com/learn/treating-seizures-and-epilepsy/seizure-medication-list; last access date October 24, 2020
- 49. Epilepsy Foundation, Epilepsy Pipeline Tracker, Landover (MD), October 2020; https://www.epilepsy.com/pipeline-listing-page; last access date October 22, 2020